|PARKINSON RESEARCH INSTITUTE
Paul A. Nausieda, MD –
Medical Director, Research Scientist
Dr. Nausieda is a board-certified neurologist nationally recognized as a sleep disorders and Parkinson disease specialist. He has written more than 100 publications on the subject of sleep and movement disorders, received many professional awards, and held numerous academic appointments including associate professorships in the department of neurological sciences and pharmacology at Rush University and the Medical College of Wisconsin. Dr. Nausieda is clinical professor of neurology at the University of Wisconsin Medical School and also is a Fellow of the American Academy of Neurology.
His current practice is one of the largest and most comprehensive in the country. He is a prominent expert and sought-after lecturer on the pharmacological treatment of PD. He has been a principal investigator in 50 drug studies of experimental therapeutic agents being tested for FDA approval and acts as a consultant to a number of pharmaceutical firms involved in the development of new treatments for Parkinson disease.
Dr. Nausieda’s determination to unveil the cause of PD was the impetus for creating the Parkinson Research Institute. As founder of the program, he bases his research ideas on the knowledge that he has gained from diagnosing and treating the disease for more than 30 years. He hopes that the information he has developed will be a catalyst for both current and future researchers.
Trevor Hyde, PhD –
Neuropsychologist, Research Scientist
Dr. Hyde received his bachelor of arts degree in psychology and philosophy from Lawrence University. He went on to earn his PhD in 2004 from Marquette University and holds a position as visiting assistant professor of psychology at Carroll College. His area of research is geriatric neuropsychology with a special focus on visuospatial memory and executive functioning. He is currently involved in multiple studies, including cognition in community-dwelling elders, neuropsychological and neurological sequelae of Gulf War syndrome, visuospatial memory and executive functioning in Parkinson disease, and caregiver stress in spouses of patients with Parkinson disease.
Dr. Hyde has published multiple manuscripts on neuropsychological consequences of anesthesia in geriatric patients with a history of alcoholism, dynamics of group problem-solving, and creative processes and productivity. Dr. Hyde has a special interest in identifying the processes of dementia and hallucinations in PD. Dr. Hyde also has an extensive background in computer programming, database design, and statistical analysis, ensuring the quality of the LifeSpan Database.
Dacy Reimer, APNP/MSN/CCRC –
Advanced Practice Nurse Practitioner, Regional Parkinson Center Coordinator, Brain Procurement Specialist, Research Scientist
Dacy Reimer is a board-certified nurse practitioner, licensed to prescribe and treat in primary care and specialized in neurology and movement disorders. She has had more than 20 years' experience in caring for individuals with Parkinson disease.
Ms. Reimer is a founding member of PRI and committed to identifying the causes of PD, with a particular interest in disease trait analysis and environmental effects. She developed the LifeSpan Database, a collection of more than 20,000 clinical patient histories and treatments. Ms. Reimer instituted the procedure for the Parkinson Research Institute Brain Procurement Program, providing 24-hour clinical service to patients and families wishing to donate brain tissues. Her role within the Parkinson Research Institute is in the development and conduction of its epidemiological research projects. She is co-author of multiple manuscripts on PD and provides research support to local university researchers. She is certified as a research coordinator by the Association of Clinical Research Professionals.
Ms. Reimer has managed more than 20 pharmaceutical studies using experimental therapeutic agents being tested for FDA approval. She works in collaboration with Dr. Nausieda as a consultant to a number of pharmaceutical firms involved in the development of new treatments for Parkinson disease.